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STUDY PROTOCOL Open Access
Neurocognitive working mechanisms of the
prevention of relapse in remitted recurrent
depression (NEWPRIDE): protocol of a
randomized controlled neuroimaging trial
of preventive cognitive therapy
Rozemarijn S. van Kleef1* , Claudi L. H. Bockting2, Evelien van Valen3, André Aleman1,
Jan-Bernard C. Marsman1 and Marie-José van Tol1
Abstract
Background: Major Depressive Disorder (MDD) is a psychiatric disorder with a highly recurrent character, making
prevention of relapse an important clinical goal. Preventive Cognitive Therapy (PCT) has been proven effective in
preventing relapse, though not for every patient. A better understanding of relapse vulnerability and working
mechanisms of preventive treatment may inform effective personalized intervention strategies. Neurocognitive models of
MDD suggest that abnormalities in prefrontal control over limbic emotion-processing areas during emotional processing
and regulation are important in understanding relapse vulnerability. Whether changes in these neurocognitive
abnormalities are induced by PCT and thus play an important role in mediating the risk for recurrent depression, is
currently unclear.
In the Neurocognitive Working Mechanisms of the Prevention of Relapse In Depression (NEWPRIDE) study, we aim to 1)
study neurocognitive factors underpinning the vulnerability for relapse, 2) understand the neurocognitive working
mechanisms of PCT, 3) predict longitudinal treatment effects based on pre-treatment neurocognitive characteristics, and
4) validate the pupil dilation response as a marker for prefrontal activity, reflecting emotion regulation capacity and
therapy success.
Methods: In this randomized controlled trial, 75 remitted recurrent MDD (rrMDD) patients will be included. Detailed
clinical and cognitive measurements, fMRI scanning and pupillometry will be performed at baseline and three-month
follow-up. In the interval, 50 rrMDD patients will be randomized to eight sessions of PCT and 25 rrMDD patients to a
waiting list. At baseline, 25 healthy control participants will be additionally included to objectify cross-sectional residual
neurocognitive abnormalities in rrMDD. After 18 months, clinical assessments of relapse status are performed to
investigate which therapy induced changes predict relapse in the 50 patients allocated to PCT.
Discussion: The present trial is the first to study the neurocognitive vulnerability factors underlying relapse and
mediating relapse prevention, their value for predicting PCT success and whether pupil dilation acts as a valuable
marker in this regard. Ultimately, a deeper understanding of relapse prevention could contribute to the development
of better targeted preventive interventions.
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Background
Rationale
Major Depressive Disorder (MDD) is the most prevalent
psychiatric disorder, with a lifetime prevalence of 19% [1]
and a highly recurrent nature [2, 3]. History of recurrence
is an important predictor of relapse [4, 5], making preven-
tion of relapse early in the course of the disease an im-
portant clinical goal. Understanding the mechanisms
facilitating relapse can give insight into the core processes
essential for relapse prevention, and may provide markers
to guide clinicians in selecting preventive strategies [6].
One way of gaining a better understanding of relapse
vulnerability is investigating the neurocognitive mecha-
nisms of existing therapeutic interventions that proved ef-
fective in preventing relapse [7, 8]. Clinically, cognitive
therapy during the depressive episode has been shown to
have an enduring preventive effect [9–11]. Applying pre-
ventive cognitive therapy (PCT; a cognitive-therapy based
psychological intervention) in the remitted state has
shown effectivity in lowering relapse-risk up to 10 years,
compared to both no therapeutic interventions and to (ta-
pering) maintenance antidepressant use [12–17]. Studying
the working mechanisms of PCT can provide insight into
which cognitive and affective processes put an individual
at risk for relapse, and which changes therein mediate a
lowered vulnerability risk following treatment.
Studies in the acute phase of MDD have shown that
cognitive therapy affects neurocognitive functioning,
including lowering cognitive biases [18, 19] and in-
creasing prefrontal cortical control over limbic struc-
tures during emotional processing [20–22]. These
processes are thought to lay at the core of the patho-
physiology of MDD [23–29], and might add to the
development and perpetuation of depression through
overrepresentation and overinterpretation of negative infor-
mation and negative affect [23, 30–33]. Several studies have
shown that abnormalities in the prefrontal cortex persist in
the remitted phase of MDD [34–37] and may predict dis-
ease course [38–43]. Furthermore, abnormal prefrontal
regulation has been related to specific MDD typical cogni-
tive processes [23, 44–49] that may persist after remission
and have been linked to recurrence, such as cognitive biases
towards negative information [49–51], heightened cognitive
reactivity to stressful situations [52–54], negative rumin-
ation [55–58], affective reactivity [59], and inadequate emo-
tion regulation (reflected in an increased tendency to
engage in, and difficulty to disengage from, negative mood
states) [32, 60, 61]. Whether the protective effect of PCT is
obtained via alternations in these neurocognitive processes
and how individual differences therein hamper such effect
is yet unknown.
Though often neglected, difficulties in processing re-
ward and maintaining positive emotions may similarly
contribute to relapse vulnerability in MDD. Abnormal-
ities in processing positive emotions have been consist-
ently associated with MDD, also in the remitted phase
[37, 62–68]. Moreover, neural responsivity in regions
important for reward processing has been related to a
history of depressive episodes [69] and both psycho-
logical and pharmacological treatment response [70]. In
acute MDD, difficulties sustaining positive emotions
have been suggested to reflect reduced fronto-striatal
capacity [71, 72]. In remitted MDD, Matsubara and col-
leagues [73] found abnormal fronto-limbic activity dur-
ing effortful regulation of positive emotions, while others
did not [61, 74]. Whether PCT obtains part of its pre-
ventive effects by impacting neurocognitive processing
of positive emotional material, is not yet known.
Aims
In the Neurocognitive Working Mechanisms of the Pre-
vention of Relapse In Depression (NEWPRIDE) study,
the neurocognitive mechanisms of preventive therapy
will be investigated using a within-subject longitudinal
comparison of cognitive biases and fMRI characteristics
related to positive and negative emotion processing be-
fore and after PCT, as compared to a waiting list control
group. At baseline, a healthy control (HC) group will be
included for cross-sectional comparison of residual
abnormalities.
The present study has four main aims. Firstly, we aim
to cross-sectionally examine whether cognitive biases
and functional magnetic resonance imaging (fMRI) re-
sponses during the regulation of positive and negative
emotions in medication-free, highly recurrent, remitted
MDD (rrMDD) patients differ from controls. We
hypothesize residual abnormalities in rrMDD patients
compared to HC in (i) an amygdala-insular-subgenual
anterior cingulate cortex (ACC)-ventrolateral prefrontal
cortex (PFC) circuitry associated with biased processing
of negative emotional information, (ii) a striatal-medial
PFC circuitry associated with biased processing of posi-
tive emotional information, and (iii) the lateral-and med-
ial PFC circuitry associated with cognitive control [75].
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Secondly, this randomized controlled fMRI-study is
the first to investigate the neurocognitive working mech-
anisms of PCT (compared to a waiting list condition) in
rrMDD patients. We hypothesize that PCT will result in
increased lateral and medial prefrontal activation, damp-
ened activation of limbic regions, and improved con-
nectivity between these regions during emotion
regulation, which will coincide with normalised process-
ing and regulation of negative information and a lowered
likelihood of a prevailing negative mood. Furthermore,
we hypothesize that increased PFC activation following
PCT relates to increased preferential processing of posi-
tive information [70, 76].
Thirdly, we aim to identify pre-treatment neurocogni-
tive markers predictive of long-term PCT success mea-
sured at 18-month follow-up. It is expected that low
pre-treatment insular and PFC activation [39, 77] and
low PFC connectivity with emotion processing areas
during emotion processing predicts favourable treatment
response [78]. Also, we hypothesize that participants
with larger pre-post differences on neurocognitive mea-
sures, will show lowest relapse up until18-month follow-
up.
Finally, we aim to investigate the value of the pupil
dilation response (PDR) as a new predictor of frontal
regulatory efforts during emotion regulation and PCT
effects as a means of providing cheaper, non-imaging,
yet imaging-informed, neurocognitive markers of
treatment-success in rrMDD [79–81]. We hypothesize
that increased PFC activation following PCT will be
reflected in an increased PDR during emotion regula-
tion, and that low pre-treatment PDR-response during
emotional regulation will be predictive of PCT effects.
Methods/design
The NEWPRIDE study is funded by the Dutch Research
Council (NWO/ZonMW grant 016.156.077) and the
Dutch Brain Foundation (Hersenstichting, Fellowship
number F2014(1)-21). The study has been approved by
the medical ethical board of the University Medical Cen-
ter Groningen (2015.284) and is in accordance with the
latest version of the Declaration of Helsinki.
Design
NEWPRIDE is an open-label randomized controlled trial
(RCT), consisting of four phases following an initial
screening: [1] a baseline clinical, neuropsychological,
fMRI- and PDR-examination (T0) [2]; a three-month
treatment phase, including either eight sessions PCT or
a waiting-list control period [3]; a post-treatment clin-
ical, neuropsychological, fMRI- and PDR-examination
(T1) 3 months after baseline, and [4] a follow-up clinical
examination (T2) 18 months after baseline. A flowchart
of the study design is provided in Fig. 1.
Participants
Recruitment
For this study, 75 rrMDD patients will be recruited, plus
25 HC participants, matched for age, sex, and education
level. We will recruit rrMDD patients who have been in
remission for over 2 months and who are highly recur-
rent (meaning having experienced two or more depres-
sive episodes in the past 5 years). Given that this
population is often no longer in care after remission, we
will primarily recruit via advertising and (social) media.
Inclusion and exclusion criteria
Criteria for inclusion for all participants are:
– Age 18 to 60 years;
– Normal intelligence (IQ > 85), as assessed with the
Dutch Adult Reading Test, or indicated by having
finished an education on at least vocational level;
– (Near) native Dutch language proficiency;
– No current DSM-IV diagnosis, according to the
Structured Clinical Interview for DSM-IV Axis I dis-
orders (SCID-I);
– No current depressive symptomatology, as indicated
by a score of 13 or less on the Inventory of
Depressive Symptomatology (IDS-SR) at the time of
inclusion;
– No past or present alcohol or drug dependency;
– No general MRI contra-indications.
We apply the following criteria specific for the rrMDD
group:
– Meeting the lifetime criteria of a DSM-IV MDD
diagnosis, according to the SCID-I;
– Currently in remission from the last Major Depressive
Episode (MDE) for more than 2 months, but not
longer than 2 years, according to the DSM-IV criteria;
– At least two MDE’s in the past 5 years;
– No regular use of psychotropic medication,
including anti-depressant medication, for at least
4 weeks;
– No cognitive (behavioural) therapy for the last MDE;
– No current or past psychotic or manic/hypomanic
episode, nor any DSM-IV developmental disorder
diagnosis.
Finally, an additional criterion for HC participants is:
– Absence of a lifetime diagnosis of any DSM-IV
disorder, as assessed with the SCID-I.
Sample size
A total of 100 participants will be included, of which 75
rrMDD patients and 25 HCs. Power analyses for
van Kleef et al. BMC Psychiatry          (2019) 19:409 Page 3 of 11
behavioural data, performed with G*Power 3.9.1.4, show
that groups of 25 are sufficient to detect moderate ef-
fects (with 80% power and α = 0.05) for both cross-
sectional group comparisons and longitudinal treatment
effect analyses. Exact power analyses for fMRI analyses
are difficult, due to the complex mass univariate nature
of the data. However, previous comparable imaging
studies yielded sufficient power with the inclusion of 20
participants per group [21, 37, 64, 70, 78, 82, 83]. We
will include a minimum of 25 (carefully selected) partici-
pants per group, to allow for loss of data due to follow-
up drop-outs.
The inclusion of 75 rrMDD patients allows for several
lines of analysis. Firstly, cross-sectional comparisons will
be carried out in 50 rrMDD patients versus 25 HCs in
order to establish residual abnormalities in emotion pro-
cessing. Because of an (unforeseen at the time of plan-
ning of the study) replacement of the MRI scanner, the
last included 25 rrMDD patients (all allotted to the
treatment condition) will be scanned on a different scan-
ner, and will therefore not be included in this analysis.
Secondly, longitudinal analyses of immediate treatment
effects will be performed in the first 50 rrMDD patients
who were randomized to either the therapy group or the
waiting list control (25 vs. 25). Finally, since it is ex-
pected that 50% of rrMDD patients relapses within 1,5
years [41, 59], an additional group of 25 rrMDD patients
will be included for the PCT condition, expanding the
Fig. 1 Flowchart providing an overview of the NEWPRIDE study design
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group of participants receiving treatment to n = 50 to
allow analyses of pre-post differences in relation to clin-
ical outcome at 18-month follow-up. Even though these
last 25 patients will be scanned on a different MRI scan-
ner, we will ensure that all participants have their pre-
and post-treatment scanning session on the same MR
machine.
Intervention
The participants in the treatment condition will receive
eight individual face-to-face sessions of PCT, a therapy
based on the cognitive model of Beck [84], developed
specifically to prevent relapse in remitted MDD patients.
The main elements of PCT are (i) identifying and chal-
lenging dysfunctional attitudes, (ii) internalising more
helpful attitudes, (iii) enhancing the formation of specific
memories of positive events, and (iv) formulating future
relapse prevention strategies [6, 85].
PCT is provided by experienced and accredited
psychologists, fully trained in cognitive behavioural ther-
apy, who have received an additional two-day training in
delivering PCT in the context of this study (by EvV and
CLHB). To establish an adequate level of treatment
integrity, therapists will strictly follow a treatment man-
ual [85] and will be supervised by a cognitive behav-
ioural therapy supervisor (EvV). Finally, the treatment
sessions will be audio-recorded to allow reviewing by the




The primary outcome of the cross-sectional assessment
of rrMDD characteristics is threefold: it concerns base-
line characteristics at T0 in (i) cognitive biases to nega-
tive and positive emotional information (measured with
the Attentional Response to Distal vs. Proximal Emo-
tional Information task (ARDPEI) [86], an adapted ver-
sion of the Emotional Reasoning Task [87] and an
Implicit Association Task (IAT) [88]); in (ii) blood oxy-
genation level dependent (BOLD) response (during an
Emotion Regulation Task (ERT) (similar as in [81, 89]),
a Verbal Working Memory Task (VWMT) [90], and
during resting state; and in (iii) the PDR during these
neurocognitive tasks.
Changes in these measures following PCT at T1 are
the main study parameters in the assessment of the
working mechanisms of PCT. The primary outcome for
the assessment of treatment predictors concerns (i) de-
pressive symptomatology, as measured with the Inven-
tory of Depressive Symptomatology self-report version
(IDS –SR30) [91] at T0, T1 and T2, and (ii) time to re-
lapse and number of relapse over the course of the
study, as measured with the Structured Clinical
Interview for DSM-IV disorders (SCID-I) [92] at T1 and
T2, in combination with the life chart method at T2.
Secondary outcome measures
Secondary parameters concern the following measures
at T0 and changes therein following therapy (at T1), as
these measurements provide additional information to
interpret and understand the changes in neurocognitive
functioning: Positive and Negative Affect Scale (PANAS)
[93], Domains and Dimensions of Pleasure Scale
(DDOPS) [94], Leuven Adaptation of the Rumination on
Sadness Scale (LARSS) [95], Emotion Regulation Ques-
tionnaire (ERQ) [96], Responses on Positive Affect ques-
tionnaire (RPA) [97], Dysfunctional Attitude Scale form
A (DAS-A) [98], NEO Five Factor Inventory (NEO-FFI)
[99], Leiden Index of Depression Sensitivity–2nd revi-
sion (LEIDS-RR) [100], Bermond-Vorst Alexithymia
Questionnaire (BVAQ) [101], and Wechsler Adult
Intelligence Scale-IV (WAIS-IV) subtests (digit-span,
letter-number sequencing, and digit-symbol substitution)
[102].
Other study parameters that will be measured during
MRI concern skin conductance reactivity (SCR), heart
rate variability (HRV), and respiration cycle (RC), in
order to provide additional measures of physiological
arousal that can explain part of the fMRI and PDR signal
and in order to remove physiological noise from the
functional MRI data.
Finally, assessment of childhood trauma (using the
Childhood Trauma Questionnaire, short form (CTQ-
SF)) [103] is performed at T0 to assess moderating ef-
fects on treatment success. At T1, the Helping Alliance
Questionnaire-II (HAQ-II) [104] will be administered in
the PCT condition to assess the role of therapeutic rela-
tionship in therapy success. At T1 and T2, the Brugha
recent life events questionnaire [105] will be administered
to obtain information on the occurrence of life events dur-
ing the trial. All questionnaires have been validated and
have shown good reliability. An overview of the assess-
ments used per treatment phase is provided in Table 1.
Procedure
Overall procedure
All data will be collected at the University Medical Cen-
ter Groningen, the Netherlands. Individuals interested in
participation will contact the researchers on their own
initiative, following public advertisement. During the
screening, the researchers will first check if the partici-
pant fully understands the study, before the participant
will sign an informed consent form. Then the SCID-I,
IDS-SR, Dutch Adult Reading Test (DART) [106], an
MRI checklist and a questionnaire with several socio-
demographic background questions will be administered,
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all to confirm that the participant meets the inclusion
criteria.
To minimize the burden on the day of scanning, a
number of questionnaires will be sent to the participants
1 week prior to the baseline assessment. During baseline
assessment the rest of the self-report questionnaires will
be administered, the cognitive tests will be performed
(ARDPEI and IAT, during which pupil dilation and gaze
tracking will be measured with the Research Eyelink
1000 Eye tracker (Mississauga, Canada), plus the Emo-
tional Reasoning Task and the WAIS-IV subtests), and
finally participants will engage in an MRI-scanning
session.
After baseline assessment, HC participants have fin-
ished their participation, and participants in the rrMDD
group undergo either eight sessions of PCT, or are in
the waiting list condition. Shortly after treatment
(3 months following baseline), the first follow-up assess-
ment T1 will be performed, in which the whole baseline
procedure will be repeated (minus the CTQ and plus the
HAQ-II and Brugha list). Eighteen months after baseline,
a shortened version of the clinical assessment (SCID-I
(including assessment of psychopathology since T0 with
the life chart method), IDS-30 and DAS) will be repeated
to assess stability of clinical state. Participants will re-
ceive 25 euro per assessment, 75 euro in total, plus reim-
bursement of travel expenses.
MRI procedure
MRI scanning will be performed on two scanners (due
to an unforeseen scanner replacement). The 25 HC and
the first 50 rrMDD subjects will be scanned on a Philips
Intera 3 Tesla MR system, equipped with a 32-channel
receiver head coil, at the NeuroImaging Center, Univer-
sity Medical Center Groningen. The last 25 rrMDD pa-
tients (all in the treatment condition) will be scanned on
a Siemens 3 Tesla Magneton Prisma MR system
(equipped with a 64-channel receiver head coil), at the
Radiology Department of the University Medical Center
Groningen, using imaging protocols harmonized to the
Philips protocols.
Table 1 Overview of assessments
Screening Baseline T0 Follow-up T1 (3 month) Follow-up T2 (18 month)
IDS-SR x x x x
SCID-I interview x









DAS x x x
PANAS x x
DDOPS x x
ARDPEI with PDR x x
IAT with PDR x x
Emotional Reasoning Task x x
WAIS-IV subtests x x
fMRI ERT with PDR + SCR + HRV + RC x x
fMRI VWMT with PDR + SCR + HRV + RC x x
fMRI Resting State with SCR + HRV + RC x x
MRI T1 with SCR + HRV + RC x x
MRI arterial spin labelling with HRV + RC x x
HAQ-II x
Brugha list x x
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The scanning procedure involves two functional echo
planar imaging (EPI)-based acquisitions (TR/TE 2000/
30 ms, 90° flip angle, voxel size 3.5 × 3.5 × 3.5 mm) to
measure BOLD contrast during the ERT and the
VWMT, one functional EPI-based acquisition (TR/TE
2000/30 ms, 70° flip angle, voxel size 3.5 × 3.5 × 3.5 mm)
sensitive to BOLD contrast during rest (RS), one T1-
weighted structural scan for anatomical reference (TR/
TE 9/3.5 ms, 8° flip angle, voxel size 1x1x1mm), and fi-
nally a pseudo-continuous arterial spin labelling
(pCASL) acquisition (TR/TE 2000/14 ms, 90° flip angle,
voxel size 3x3x3).
During the ERT, VWMT and RS acquisitions, simul-
taneous pupillometry will be recorded using an SR-
Research MR-compatible Eyelink system (Mississauga,
Canada). Besides changes in brain activation and pupil
dilation, autonomic responses to emotional events and
stimuli include increased skin conductance reactivity
(SCR) and changes in cardiovascular activity (HRV)
[107]. We will measure SCR during MRI scanning using
an MR-compatible Direct Current Galvanic Skin Re-
sponse MR sensor interfaced with the BrainAmp ExG
MR amplifier (Brain Products, GmbH) by applying a
constant voltage (.5 V) between two sintered Ag/AgCl
electrodes attached to the palmar surface of the distal
phalanges of the index and middle fingers of the left
hand. Furthermore, HRV signal will be recorded during
scanning, logging the R-top trigger produced by the
standard cardiac equipment of the Philips and Siemens
MRI systems. In order to correct for additional noise,
respiratory rate and depth will be measured through
pressure variation in a cushion that is fastened around
the participant’s abdomen. Finally, before every fMRI
acquisition, the state tension levels of the participant will
be monitored, by asking them how tense they feel on a
Visual Analogue Scale.
Randomization
Allocation sequence will be based on computer-
generated random numbers. The first 50 rrMDD pa-
tients will be randomized over either the treatment con-
dition or the waiting list control condition, to allow for
instantaneous analysis of immediate PCT effects after in-
clusion of these participants. The 25 last included
rrMDD patients will be allotted to the treatment condi-
tion, but will be given the same information (and thus
hold the same expectations regarding their chance of
being in the treatment condition). Patients and the prin-
cipal investigators will not be blind to the treatment
condition. However, to ensure unbiased assessment of
clinical state and neuropsychological testing, the
researchers who are involved in further assessments will
be kept blind, and participants will be asked not to in-
form the assessor on their allotted condition.
Statistical analyses
Questionnaire and behavioural data
Cross-sectional residual characteristics of remitted MDD
will be tested with a (Repeated Measures-, in case of
highly correlated task conditions) AN(C) OVA proced-
ure. The effects of PCT as measured with questionnaires
and cognitive tests before and after treatment will be
analysed within a multi-level analysis framework. Appro-
priate nonparametric tests (e.g. Friedman test) will be
used if warranted. Effects will be considered significant
at p < .05. Age, sex, and education level will be added as
covariates.
MRI data
Quality of BOLD fMRI data will be extensively checked,
before data will be pre-processed according to standard
recommended procedures. Subsequently, data will be
modelled on the subject level using onsets/duration for
the different task conditions, or time-course information.
On the second level, between-group comparisons will be
performed in order to analyse residual abnormalities in
emotion regulation capacity, verbal working memory
performance and resting state-perfusion and functional
connectivity. A multilevel analysis model will be set up
to test for the effects of treatment on these measures.
Furthermore, linear modelling will be applied to identify
and test the predictors of long-term treatment success,
as defined by symptomatology (at T0, T1, T2) and re-
lapse status and course (T1-T2) in the larger sample of
remitted patients who have received therapy. Multivari-
ate pattern analysis will be performed to evaluate the
predictive value of post-treatment characteristics and
pre-treatment changes for long-term treatment success.
Effects will be considered significant at p < .05, corrected
for multiple comparisons.
Pupillometry data
Pupillometry data will be corrected for eye blinks and
modelled to task data. Summary statistics will be entered
in (Repeated Measures-)AN(C) OVAs, multi-level
models and linear regression models. Effects will be con-
sidered significant at p < .05 after appropriate correction
for multiple comparisons. To investigate whether PDR
measurements have value for predicting frontal brain
activation during emotion regulation, the PDR will be
related to functional activation of regions implicated in
effortful emotion regulation using multiple regression,
while controlling for the arousal component of the sym-
pathetic response, in the form of variation in SCR and
HRV.
To investigate whether these relations are unique for
effortful emotion regulation, linear regression models of
the PDR during effortful emotion regulation (ERT) and
during working memory (VWMT) will be set up and
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compared. Finally, it will be investigated whether treat-
ment success can be predicted from multivariate pat-
terns based on information from different modalities.
Discussion
The high prevalence of recurrence in MDD poses a
major clinical challenge and requires a better under-
standing of relapse vulnerability and of factors under-
lying preventive therapy success [108]. Recent reports
explicitly call for combined neuroscientific and clinical
research to improve current treatment [8, 109, 110]. The
NEWPRIDE trial will be the first to study working
mechanisms and predictors of Preventive Cognitive
Therapy by examining neurophysiological and cognitive
processes associated with attentional processing and
regulation of both positive and negative emotional
information.
In this RCT, we examine vulnerability for relapse by
comparing pre-treatment neurocognitive processing in
rrMDD with a group of HC, and we investigate hypothe-
sized changes induced by PCT as compared to a waiting
list control condition. Clinical, cognitive, and fMRI assess-
ments in the remitted patient group are performed imme-
diate and 15months after treatment, to gain insight in the
working mechanisms of preventive cognitive therapy and
to examine predictors of relapse and relapse prevention.
One of the main strengths of the present study is the
composition of the patient sample: only highly recurrent
remitted MDD patients are included, allowing for the
thorough examination of relapse mechanisms. Further-
more, given the expected relapse rate of 50% within 1,5
years follow-up, the relatively high recurrence in the
present sample makes it possible to study predictors of
(prevention of) relapse. The lack of confounding anti-
depressant medication use, recent cognitive therapy use,
or current comorbid psychiatric diagnoses makes for a
clean examination of residual characteristics and therapy
effects. Another strength is the thorough investigation of
clinical and neurocognitive features in this study, provid-
ing a broad and extensive investigation of mechanisms
facilitating vulnerability and prevention of relapse.
A methodological difficulty of the follow-up design is
the risk of participants dropping out, a risk enlarged by
the expected amount of relapse. If possible, participants
who drop out will be replaced. For the longitudinal
analysis, the number of included participants will be suf-
ficient to allow for an estimated 20% loss of participants
and to detect an expected medium-sized within-group
treatment effect. Furthermore, the fact that the last
group of participants is scanned on a different MR-
scanner might lead to higher between-group variance.
Fortunately, the scanner change only affects the longitu-
dinal analyses of PCT success prediction in the treat-
ment condition. Since we anticipate a 50% relapse in
both first-scanner and second-scanner participant group,
and because pre- and post-treatment scanning is per-
formed on the same scanner in all participants, we ex-
pect that any effect of the scanners will be equally
divided between the relapse- and no-relapse groups,
thereby minimizing possible limiting effects of the scan-
ner change.
Conclusion
In conclusion, by examining neurocognitive characteris-
tics of rrMDD, the NEWPRIDE study will provide more
insight in vulnerability to relapse and working mecha-
nisms of psychological relapse prevention interventions.
Unravelling the mechanisms of relapse prevention will
improve our understanding of changes that are needed
to lower an individual’s relapse vulnerability and may
add to the development of more targeted and persona-
lised interventions. Furthermore, results of the study
may lead to the identification of neurocognitive predic-
tors of both individual relapse risk and the chance that
an individual might benefit from PCT, based on charac-
teristics in the remitted phase. Finally, as routinely per-
forming neuroimaging investigations for predicting
treatment success is clinically not feasible, this study
aims to validate the PDR as a marker of brain activation
during emotion regulation in remitted MDD, for use in
innovative non-imaging, brain-informed prediction and
monitoring of PCT success.
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